Imperial College London

Emeritus ProfessorAnitaSimonds

Faculty of MedicineNational Heart & Lung Institute

Emeritus Professor of Respiratory & Sleep Medicine
 
 
 
//

Contact

 

+44 (0)20 7351 8911a.simonds

 
 
//

Location

 

Office by Sleep LabsFulham RoadRoyal Brompton Campus

//

Summary

 

Publications

Publication Type
Year
to

235 results found

Simonds AK, 2022, How Many More Nights? Diagnosing and Classifying Obstructive Sleep Apnea Using Multinight Home Studies, AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol: 205, Pages: 491-492, ISSN: 1073-449X

Journal article

Winslow RL, Zhou J, Windle EF, Nur I, Lall R, Ji C, Millar JE, Dark PM, Naisbitt J, Simonds A, Dunning J, Barclay W, Baillie JK, Perkins GD, Semple MG, McAuley DF, Green CAet al., 2022, SARS-CoV-2 environmental contamination from hospitalised patients with COVID-19 receiving aerosol-generating procedures, THORAX, Vol: 77, Pages: 259-267, ISSN: 0040-6376

Journal article

Perkins GD, Ji C, Connolly BA, Couper K, Lall R, Baillie JK, Bradley JM, Dark P, Dave C, De Soyza A, Dennis A, Devrell A, Fairbairn S, Ghani H, Gorman EA, Green CA, Hart N, Hee SW, Kimbley Z, Madathil S, McGowan N, Messer B, Naisbitt J, Norman C, Parekh D, Parkin EM, Patel J, Regan SE, Ross C, Rostron AJ, Saim M, Simonds AK, Skilton E, Stallard N, Steiner M, Vancheeswaran R, Yeung J, McAuley DFet al., 2022, Effect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients With Acute Hypoxemic Respiratory Failure and COVID-19 The RECOVERY-RS Randomized Clinical Trial, JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, Vol: 327, Pages: 546-558, ISSN: 0098-7484

Journal article

Rajesh S, Wonderling D, Simonds AK, 2021, Obstructive sleep apnoea/hypopnoea syndrome and obesity hyperventilation syndrome in over 16s: summary of NICE guidance, BMJ-BRITISH MEDICAL JOURNAL, Vol: 375, ISSN: 0959-535X

Journal article

van den Berge M, Genton C, Heuvelin E, Simonds AK, Humbert M, Nyberg A, Gosens R, Donnelly L, Fulton O, Wilkens M, Roche N, Brightling Cet al., 2021, Success and continuous growth of the ERS clinical research collaborations, EUROPEAN RESPIRATORY JOURNAL, Vol: 58, ISSN: 0903-1936

Journal article

Lebret M, Leotard A, Pepin JL, Windisch W, Ekkernkamp E, Pallero M, Sanchez-Quiroga M-A, Hart N, Kelly JL, Patout M, Funk GC, Duiverman ML, Masa JF, Simonds A, Murphy PB, Wijkstra PJ, Dreher M, Storre J, Khouri C, Borel J-Cet al., 2021, Nasal versus oronasal masks for home non-invasive ventilation in patients with chronic hypercapnia: a systematic review and individual participant data meta-analysis, THORAX, Vol: 76, Pages: 1108-1116, ISSN: 0040-6376

Journal article

Schiza S, Levy P, Martinez-Garcia MA, Pepin J-L, Simonds A, Randerath Wet al., 2021, The search for realistic evidence on the outcomes of obstructive sleep apnoea, EUROPEAN RESPIRATORY JOURNAL, Vol: 58, ISSN: 0903-1936

Journal article

Humbert M, Simonds AK, 2021, Looking forward: key initiatives to improve the care of rare diseases and streamline the delivery of medicines and vaccines in Europe, AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, Vol: 321, Pages: L616-L618, ISSN: 1040-0605

Journal article

Cowie MR, Linz D, Redline S, Somers VK, Simonds AKet al., 2021, Sleep Disordered Breathing and Cardiovascular Disease <i>JACC</i> State-of-the-Art Review, JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol: 78, Pages: 608-624, ISSN: 0735-1097

Journal article

Cilloniz C, Simonds A, Hansen K, Alouch J, Zar H, Nakanishi Y, Levine S, Cohen M, Dela Cruz C, Evans SE, Sanguinetti M, Vila J, Manglano JD, Ferrer R, Criado L, Garcia JP, Correcher Z, Rodriguez-Hurtado D, Terrazas C, Munoz-Almagro C, Garcia-Vidal C, Aoun Z, Amirav Iet al., 2021, Pulse oximetry is an essential tool that saves lives: a call for standardisation, EUROPEAN RESPIRATORY JOURNAL, Vol: 57, ISSN: 0903-1936

Journal article

Chalmers JD, Crichton ML, Goeminne PC, Cao B, Humbert M, Shteinberg M, Antoniou KM, Ulrik CS, Parks H, Wang C, Vandendriessche T, Qu J, Stolz D, Brightling C, Welte T, Aliberti S, Simonds AK, Tonia T, Roche Net al., 2021, Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline, EUROPEAN RESPIRATORY JOURNAL, Vol: 57, ISSN: 0903-1936

Journal article

Schiza S, Simonds A, Randerath W, Fanfulla F, Testelmans D, Grote L, Montserrat JM, Pepin J-L, Verbraecken J, Ersu R, Bonsignore MRet al., 2021, Sleep laboratories reopening and COVID-19: a European perspective, EUROPEAN RESPIRATORY JOURNAL, Vol: 57, ISSN: 0903-1936

Journal article

Chen Y, Postmus D, Cowie MR, Woehrle H, Wegscheider K, Simonds AK, Boezen M, Somers VK, Teschler H, Eulenburg Cet al., 2021, Using joint modelling to assess the association between a time-varying biomarker and a survival outcome: an illustrative example in respiratory medicine, EUROPEAN RESPIRATORY JOURNAL, Vol: 57, ISSN: 0903-1936

Journal article

Roche N, Tonia T, Bush A, Brightling C, Kolb M, Anh TD-X, Humbert M, Simonds A, Adir Yet al., 2020, Guidance production before evidence generation for critical issues: the example of COVID-19, EUROPEAN RESPIRATORY REVIEW, Vol: 29, ISSN: 0905-9180

Journal article

Janssen DJA, Ekstroem M, Currow DC, Johnson MJ, Maddocks M, Simonds AK, Tonia T, Marsaa Ket al., 2020, COVID-19: guidance on palliative care from a European Respiratory Society international task force, EUROPEAN RESPIRATORY JOURNAL, Vol: 56, ISSN: 0903-1936

Journal article

Trucco F, Carruthers E, Davies JC, Simonds AK, Bush A, Tan H-Let al., 2020, Inflammation in children with neuromuscular disorders and sleep disordered breathing, SLEEP MEDICINE, Vol: 72, Pages: 118-121, ISSN: 1389-9457

Journal article

Perkins GD, Couper K, Connolly B, Baillie JK, Bradley JM, Dark P, De Soyza A, Gorman E, Gray A, Hamilton L, Hart N, Ji C, Lall R, McGowan N, Regan S, Simonds AK, Skilton E, Stallard N, Stimpson E, Yeung J, McAuley DFet al., 2020, RECOVERY- Respiratory Support: Respiratory Strategies for patients with suspected or proven COVID-19 respiratory failure; Continuous Positive Airway Pressure, High-flow Nasal Oxygen, and standard care: A structured summary of a study protocol for a randomised controlled trial, TRIALS, Vol: 21

Journal article

Simonds AK, 2020, 'Led by the science', evidence gaps, and the risks of aerosol transmission of SARS-COV-2, RESUSCITATION, Vol: 152, Pages: 205-207, ISSN: 0300-9572

Journal article

Wimms AJ, Kelly JL, Turnbull CD, McMillan A, Craig SE, O'Reilly JF, Nickol AH, Hedley EL, Decker MD, Willes LA, Calverley PMA, Benjafield AV, Stradling JR, Morrell MJ, MERGE trial investigatorset al., 2020, Continuous positive airway pressure versus standard care for the treatment of people with mild obstructive sleep apnoea (MERGE): a multicentre, randomised controlled trial, The Lancet Respiratory Medicine, Vol: 8, Pages: 349-358, ISSN: 2213-2600

BACKGROUND: The evidence base for the treatment of mild obstructive sleep apnoea is limited and definitions of disease severity vary. The MERGE trial investigated the clinical effectiveness of continuous positive airway pressure in patients with mild obstructive sleep apnoea. METHODS: MERGE, a multicentre, parallel, randomised controlled trial enrolled patients (≥18 years to ≤80 years) with mild obstructive sleep apnoea (apnoea-hypopnoea index [AHI] ≥5 to ≤15 events per h using either AASM 2007 or AASM 2012 scoring criteria) from 11 UK sleep centres. Participants were assigned (1:1) to either 3 months of continuous positive airway pressure plus standard care (sleep counselling), or standard care alone, by computer-generated randomisation; neither participants nor researchers were blinded. The primary outcome was a change in the score on the Short Form-36 questionnaire vitality scale in the intention-to-treat population of patients with mild obstructive sleep apnoea diagnosed using the American Academy of Sleep Medicine 2012 scoring criteria. The study is registered with ClinicalTrials.gov, NCT02699463. FINDINGS: Between Nov 28, 2016 and Feb 12, 2019, 301 patients were recruited and randomised. 233 had mild obstructive sleep apnoea using AASM 2012 criteria and were included in the intention-to-treat analysis: 115 were allocated to receive continuous positive airway pressure and 118 to receive standard care. 209 (90%) of these participants completed the trial. The vitality score significantly increased with a treatment effect of a mean of 10·0 points (95% CI 7·2-12·8; p<0·0001) after 3 months of continuous positive airway pressure, compared with standard care alone (9·2 points [6·8 to 11·6] vs -0·8 points [-3·2 to 1·5]). Using the ANCOVA last-observation-carried-forward analysis, a more conservative estimate, the vitality score also significantly increased with a treatment effect of a

Journal article

Ferreira JP, Duarte K, Woehrle H, Cowie MR, Wegscheider K, Angermann C, d'Ortho M-P, Erdmann E, Levy P, Simonds AK, Somers VK, Teschler H, Rossignol P, Koenig W, Zannad Fet al., 2020, Biomarkers in patients with heart failure and central sleep apnoea: findings from the SERVE-HF trial, ESC Heart Failure, Vol: 7, Pages: 503-511, ISSN: 2055-5822

AimsThe Treatment of Sleep‐Disordered Breathing with Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients with Heart Failure trial investigated the effects of adaptive servo‐ventilation (ASV) (vs. control) on outcomes of 1325 patients with heart failure and reduced ejection fraction (HFrEF) and central sleep apnoea (CSA). The primary outcome (a composite of all‐cause death or unplanned HF hospitalization) did not differ between the two groups. However, all‐cause and cardiovascular (CV) mortality were higher in the ASV group. Circulating biomarkers may help in better ascertain patients' risk, and this is the first study applying a large set of circulating biomarkers in patients with both HFrEF and CSA.Methods and resultsCirculating protein‐biomarkers (n = 276) ontologically involved in CV pathways, were studied in 749 (57% of the trial population) patients (biomarker substudy), to investigate their association with the study outcomes (primary outcome, CV death and all‐cause death). The mean age was 69 ± 10 years, and > 90% were male. The groups (ASV vs. control and biomarker substudy vs. no biomarker) were well balanced. The “best” clinical prognostic model included male sex, systolic blood pressure < 120 mmHg, diabetes, loop diuretic, cardiac device, 6‐min walking test distance, and N‐terminal pro BNP as the strongest prognosticators. On top of the “best” clinical prognostic model, the biomarkers that significantly improved both the discrimination (c‐index) and the net reclassification index (NRI) of the model were soluble suppression of tumorigenicity 2 for the primary outcome; neurogenic locus notch homolog protein 3 (Notch‐3) for CV‐death and all‐cause death; and growth differentiation factor 15 (GDF‐15) for all‐cause death only.ConclusionsWe studied 276 circulating biomarkers in patients with HFrEF and central sleep apnoea; of these biomarkers, three added significant prognostic information on top of the

Journal article

Schiza SE, Randerath W, Sanchez-de-la-Torre M, Aliverti A, Bonsignore MR, Simonds AK, Laveneziana Pet al., 2020, Continuous professional development: elevating sleep and breathing disorder education in Europe, BREATHE, Vol: 16, ISSN: 1810-6838

Journal article

Javed F, Tamisier R, Pepin J-L, Cowie MR, Wegscheider K, Angermann C, D'Ortho M-P, Erdmann E, Simonds AK, Somers VK, Teschler H, Levy P, Armitstead J, Woehrle Het al., 2020, Association of serious adverse events with Cheyne-Stokes respiration characteristics in patients with systolic heart failure and central sleep apnoea: A SERVE-Heart Failure substudy analysis, RESPIROLOGY, Vol: 25, Pages: 305-311, ISSN: 1323-7799

Journal article

Chatwin M, Simonds AK, 2020, Long-Term Mechanical Insufflation-Exsufflation Cough Assistance in Neuromuscular Disease: Patterns of Use and Lessons for Application, RESPIRATORY CARE, Vol: 65, Pages: 135-143, ISSN: 0020-1324

Journal article

Gaga M, Stolz D, Chorostowska-Wynimko J, Welte T, Simonds Aet al., 2020, Respiratory medicine is not gender blind, EUROPEAN RESPIRATORY JOURNAL, Vol: 55, ISSN: 0903-1936

Journal article

Ferreira JP, Duarte K, Woehrle H, Cowie MR, Angermann C, d'Ortho M-P, Erdmann E, Levy P, Simonds AK, Somers VK, Teschler H, Wegscheider K, Bresso E, Dominique-Devignes M, Rossignol P, Koenig W, Zannad Fet al., 2019, Bioprofiles and mechanistic pathways associated with Cheyne-Stokes respiration: insights from the SERVE-HF trial, Clinical Research in Cardiology, Pages: 1-11, ISSN: 0300-5860

IntroductionThe SERVE-HF trial included patients with heart failure and reduced ejection fraction (HFrEF) with sleep-disordered breathing, randomly assigned to treatment with Adaptive-Servo Ventilation (ASV) or control. The primary outcome was the first event of death from any cause, lifesaving cardiovascular intervention, or unplanned hospitalization for worsening heart failure. A subgroup analysis of the SERVE-HF trial suggested that patients with Cheyne-Stokes respiration (CSR) < 20% (low CSR) experienced a beneficial effect from ASV, whereas in patients with CSR ≥ 20% ASV might have been harmful. Identifying the proteomic signatures and the underlying mechanistic pathways expressed in patients with CSR could help generating hypothesis for future research.MethodsUsing a large set of circulating protein-biomarkers (n = 276, available in 749 patients; 57% of the SERVE-HF population) we sought to investigate the proteins associated with CSR and to study the underlying mechanisms that these circulating proteins might represent.ResultsThe mean age was 69 ± 10 years and > 90% were male. Patients with CSR < 20% (n = 139) had less apnoea-hypopnea index (AHI) events per hour and less oxygen desaturation. Patients with CSR < 20% might have experienced a beneficial effect of ASV treatment (primary outcome HR [95% CI] = 0.55 [0.34–0.88]; p = 0.012), whereas those with CSR ≥ 20% might have experienced a detrimental effect of ASV treatment (primary outcome HR [95% CI] = 1.39 [1.09–1.76]; p = 0.008); p for interaction = 0.001. Of the 276 studied biomarkers, 8 were associated with CSR (after adjustment and with a FDR1%-corrected p value). For example, higher PAR-1 and ITGB2 levels were associated with higher odds of having CSR < 20%

Journal article

Woehrle H, Cowie MR, Wegscheider K, Vettorazzi E, Angermann C, D'Ortho M-P, Erdmann E, Levy P, Simonds AK, Somers VK, Zannad F, Teschler Het al., 2019, No effect of adaptive servo-ventilation (ASV) device used on outcomes in SERVE-HF, EUROPEAN RESPIRATORY JOURNAL, Vol: 54, ISSN: 0903-1936

Journal article

Simonds A, 2019, Confidences de Salon, BREATHE, Vol: 15, Pages: 260-261, ISSN: 1810-6838

Journal article

Gaga M, Powell P, Almagro M, Tsiligianni I, Loukides S, Roca J, Cullen M, Simonds AK, Ward B, Saraiva I, Troosters T, Cordeiro CRet al., 2019, ERS Presidential Summit 2018: multimorbidities and the ageing population, ERJ OPEN RESEARCH, Vol: 5

Journal article

Kumar R, Fadieieva H, Chipev PM, Simonds Aet al., 2019, Noninvasive ventilation (advanced): course report, BREATHE, Vol: 15, Pages: 104-107, ISSN: 1810-6838

Journal article

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://wlsprd.imperial.ac.uk:80/respub/WEB-INF/jsp/search-html.jsp Request URI: /respub/WEB-INF/jsp/search-html.jsp Query String: respub-action=search.html&id=00162507&limit=30&person=true